Related Experiment Video
Updated: Jun 18, 2025
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma
Yufei Lan1, Xiaodie Li1, Boyang Liu2
1Department of Neurosurgery, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, The Neurosurgery Institute of Guangdong Province, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China.
Novel DNA nanoparticles effectively deliver siRNA to silence O6-methylguanine DNA methyltransferase (MGMT) in glioblastoma (GBM). This approach enhances temozolomide (TMZ) efficacy by overcoming delivery barriers for improved GBM treatment.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cancer Therapeutics
Background:
- O6-methylguanine DNA methyltransferase (MGMT) expression dictates temozolomide (TMZ) sensitivity in glioblastoma (GBM).
- siRNA delivery for MGMT inhibition is challenged by degradation, off-target effects, and poor tumor accumulation.
Purpose of the Study:
- To develop a novel nanocarrier for efficient siRNA delivery to target MGMT in GBM.
- To enhance the therapeutic efficacy of temozolomide in glioblastoma treatment.
Main Methods:
- Construction of framework nucleic acid nanoparticles (FNN) encapsulating siMGMT.
- Conjugation of Angiopep-2 (ANG) for blood-brain barrier (BBB) penetration and GBM targeting.
- Engineering of Nucleolin (NCL)-responsive locks for controlled siMGMT release.
Main Results:
- FNN successfully encapsulated and protected siMGMT.
- ANG conjugation facilitated BBB crossing and GBM targeting.
- NCL-responsive locks enabled tumor-specific siMGMT release, leading to MGMT suppression.
- Significant improvement in TMZ therapeutic efficacy was observed in GBM models.
Conclusions:
- The developed FNN system represents a promising strategy for targeted siRNA delivery in GBM.
- This innovative approach overcomes current limitations in siRNA-based cancer therapy.
- The strategy holds potential to significantly advance glioblastoma treatment paradigms.
